Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A generic drug combination synergizes as exercise enhancers to ameliorate various metabolically-related diseases

ABSTRACT: To confirm if the combination of A and B therapy is beneficial for metabolic disease, we fed genetically obese Lepob/Lepob mice with a high fat, high fructose, high cholesterol diet ad libitum, to establish liver steatosis and moderate fibrosis in a way that faithfully recapitulates key features of human metabolic disease. And we performed gene expression analysis on muscle and liver from metabolic disease mice after treatment. 24 hours after drug treatment, the quadriceps muscle significantly upregulating gene signatures for innervation (NGF signaling), mitochondrial fatty acid oxidation (FAO) and vascularization (VEGF signaling). In the liver there was an increase in liver development genes and an increase in mitochondrial genes 24 hours after drug treatment. After 40 days of treatment, the drug treatment increased insulin-PI3K-mTOR signaling and neuromuscular Slit-Robo signaling, while decreasing extracellular matrix collagen production and fatty acid metabolism in muscles. The drug treatment increased anti-inflammatory signatures while decreasing lipogenesis signaling in the live. Taken together, our data showed that the liver is reversing steatosis and inflammation, and the muscle increased muscle insulin signaling sensitivity and function in metabolic disease after the drug treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE255008 | GEO | 2026/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human fatty liver RT-PCR array on primary human hepatocytes grown with 3t3-J2 stromal cells in a micropatterned co-culture

Project description:Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, progressive disorder and growing public health concern. To address this issue considerable research has been undertaken in pursuit of new NAFLD therapeutics. Development of effective, high-throughput in vitro models is an important aspect of drug discovery. Here, a micropatterned hepatocyte co-culture (MPCC) was used to model liver steatosis. The MPCC model (HEPATOPAC) involves hepatocytes and 3T3-J2 mouse stromal cells patterned onto a standard 96-well plate, increasing throughput and allowing the cultures to be handled and imaged like 2D cultures. These studies employed high content imaging (HCI) analysis to assess lipid content in cultures. HCI analysis of lipid accumulation allows large numbers of samples to be imaged and analyzed in a relatively short period of time compared to manual acquisition and analysis methods. Treatment of MPCC with free fatty acids (FFA), high glucose and fructose (HGF), or a combination o f both induces hepatic steatosis. MPCC treatment with ACC1/ACC2 inhibitors, as either a preventative or reversal agent showed efficacy against FFA induced hepatic steatosis. Drug induced steatosis was also evaluated. Treatment with valproic acid showed steatosis induction in a lean background, which was significantly potentiated in a fatty liver background. Additionally, these media treatments changed expression of fatty liver related genes. Treatment of MPCC with FFA, HGF, or a combination reversibly altered expression of genes involved in fatty acid metabolism, insulin signaling, and lipid transport. Together, these data demonstrate that MPCC is an easy to use, long-term functional in vitro model of NAFLD having utility for compound screening, drug toxicity evaluation, and assessment of gene expression changes.

2023-09-22 | GSE240886 | GEO

RNAseq analysis of liver transcriptomes from wild-type and MLL4SETf/fHSA-Cre mice

Project description:Evidence is emerging that skeletal muscle metabolic reprogramming could be a modifier of hepatic steatosis. Skeletal muscle-specific Mll4-knockout (MLL4SETf/fHSA-Cre) and wild-type (WT) littermates were placed on HFD (60% kcal from fat). Interestingly, muscle MLL4 deficiency prevents HFD-induced hepatic steatosis. To gain insight into the liver metabolic reprogramming in MLL4SETf/fHSA-Cre mice, we performed RNA-Seq analysis on mRNA isolated from liver of the MLL4SETf/fHSA-Cre mice and littermate controls. Gene ontology (GO) analysis of down-regulated genes revealed significant enrichment in lipid metabolic process, inflammatory response as well as collagen fibril organization. Conversely, pathways of oxidation-reduction and epoxygenase P450 were significantly enriched in the upregulated gene set. Gene expression validation studies demonstrated that the expression of the gene encoding lipid uptake and de novo lipogenesis was reduced in HFD-fed MLL4SETf/fHSA-Cre liver, concomitant with an increased in the expression of the oxidation-reduction genes. These findings suggest that MLL4 deletion in skeletal muscle decreases lipid uptake and denovo lipogenesis in the liver, leading to protection from HFD-induced hepatic steatosis.

2025-10-18 | GSE206416 | GEO

Periodontal pathogen induces entero-hepatic metabolic derangements in type 2 diabetic mouse model

Project description:This is the first report of the metabolic and metaproteomic integrated changes in the gut and liver by the swallowed periodontopathogen. Periodontal disease pathogen Porphyromonas gingivalis are observed in faeces as peptides level in proteomic analysis and make changes in bowel microbial composition in db/db mouse. Orally Periodontal disease pathogen throwing as experimental periodontal disease model make gluconeogenesis in db/db mouse liver and hyperglycemia. Multi-omics analysis reveal Pg decreasing in energy metabolism and glucagon store in db/db mouse liver. These findings suggest that periodontal treatment improving oral microbiota can make diabetic hyperglycemia ameliorate in liver and support these diabetes treatments credibly.

2021-09-21 | PXD021851 | JPOST Repository

Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction Associated Steatotic Liver Disease

Project description:Emerging evidence suggests that the peptide hormone kisspeptin, signaling via the kisspeptin 1 receptor (KISS1R), decreases hepatic steatosis and protects against metabolic dysfunction-associated steatotic liver disease (MASLD). De novo lipogenesis (DNL) is a key contributor to the pathogenesis of MASLD. This study aimed to determine whether kisspeptin treatment of obese, diabetic mice directly attenuates DNL. DNL was assessed in kisspeptin-treated (KPA) or phosphate-buffer saline (PBS)-treated mouse livers, using a mouse model of MASLD employing metabolic tracing using 2H2O-enriched water and mass spectrometry. Kisspeptin-treated steatotic livers demonstrated a decrease in DNL of free fatty acids (FFA), known to be associated with type 2 diabetes, steatosis, and hepatocellular carcinoma. Enhancement of KISS1R signaling has a therapeutic effect in limiting DNL, suggesting a crucial role in restricting the pathogenesis and progression of MASLD.

2025-05-29 | MSV000098033 | MassIVE

Expression data from leptin administration to Lepob/Lepob mice and Lepmkyo/Lepmkyo rats

Project description:Leptin-responsive genes in the pathway of a leptin signal from the hypothalamus to the liver has not been detected. We used microarray to detailed the expression of gene in liver in the status of leptin deficiency, and leptin administration. As leptin deficient status, we use Lepmkyo/Lepmkyo rats or Lepob/Lepob mice and their wild type littermates. Recombinant murine leptin (1 microg/mg) and saline was intraperitonealy administrated in 20 weeks old Lepob/Lepob mice and their control littermates, and 20 weeks old Lepmkyo/Lepmkyo rats and their control littermates. In order to detect the early response genes whose expression level were changed before the food intake and body weight would change, we took liver samples 6 hours after administration.

2012-11-28 | E-GEOD-42532 | biostudies-arrayexpress

Raw data for manuscript : "Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD"

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one third of the global population. Understanding metabolic pathways involved can provide insights into disease progression and treatment. Untargeted metabolomics of livers from mice with early-stage steatosis uncovered decreased methylated metabolites, suggesting altered one-carbon metabolism. The levels of glycine, a central component of one-carbon metabolism, were lower in mice with hepatic steatosis, consistent with clinical evidence. Stable-isotope tracing demonstrated that increased serine synthesis from glycine via reverse serine hydroxymethyltransferase (SHMT) is the underlying cause for decreased glycine in steatotic livers. Consequently, limited glycine availability in steatotic livers impaired glutathione synthesis under acetaminophen-induced oxidative stress, enhancing acute hepatotoxicity. Glycine supplementation or hepatocyte-specific ablation of the mitochondrial SHMT2 isoform in mice with hepatic steatosis mitigated acetaminophen-induced hepatotoxicity by supporting de novo glutathione synthesis. Thus, early metabolic changes in MASLD that limit glycine availability sensitize mice to xenobiotics even at the reversible stage of this disease.

2023-12-12 | MSV000093653 | MassIVE

Lysine tRNA fragments and miR-194-5p co-regulate hepatic steatosis via β-Klotho and Perilipin 2 (small RNA II)

Project description:Non-alcoholic fatty liver disease (NAFLD) involves hepatic accumulation of intracellular lipid droplets via incompletely understood processes. Here, we report distinct and cooperative NAFLD roles of LysTTT-5’tRF transfer RNA fragments and microRNA miR-194-5p. Unlike lean animals, dietary-induced NAFLD mice showed concurrent hepatic decrease of both LysTTT-5’tRF and miR-194-5p levels, which were restored following miR-132 antisense oligonucleotide treatment which suppresses hepatic steatosis. Moreover, exposing human-derived Hep G2 cells to oleic acid for 7 days co-suppressed miR-194-5p and LysTTT-5’tRF levels while increasing lipid accumulation. Importantly, transfecting fattened cells with a synthetic LysTTT-5’tRF mimic elevated mRNA levels of the metabolic regulator β-Klotho while decreasing triglyceride amounts by 30% within 24 hours. In contradistinction, antisense suppression of miR-194-5p induced accumulation of its novel target, the NAFLD-implicated lipid droplet-coating PLIN2 protein. Further, two out of 15 steatosis-alleviating screened drug-repurposing compounds, Danazol and Latanoprost, elevated miR-194-5p or LysTTT-5’tRF levels. The different yet complementary roles of miR-194-5p and LysTTT-5’tRF offer new insights into the complex roles of small non-coding RNAs and the multiple pathways involved in NAFLD pathogenesis.

2024-01-31 | GSE248319 | GEO

Lysine tRNA fragments and miR-194-5p co-regulate hepatic steatosis via β-Klotho and Perilipin 2 (RNA)

2024-01-31 | GSE248320 | GEO

Lysine tRNA fragments and miR-194-5p co-regulate hepatic steatosis via β-Klotho and Perilipin 2 (small RNA I)

2024-01-31 | GSE248317 | GEO

Liver-specific FGFR4 knockdown in mice on a HFD increases bile acid synthesis and improves hepatic steatosis II

Project description:Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increased risk in patients with metabolic syndrome. There are no FDA approved treatments, but farnesoid X receptor (FXR) agonists have shown promising results in clinical studies for NAFLD management. In addition to FXR, fibroblast growth factor receptor FGFR4 is a key mediator of hepatic bile acid synthesis. Using N-acetylgalactosamine-conjugated siRNA, we knocked down FGFR4 specifically in the liver of mice on chow or high-fat diet (HFD) and in mouse primary hepatocytes to determine the role of FGFR4 in metabolic processes and hepatic steatosis. Liver-specific FGFR4 silencing increased bile acid production and lowered serum cholesterol. Additionally, we found that HFD-induced liver steatosis and insulin resistance improved following FGFR4 knockdown. These improvements were associated with activation of the FXR-FGF15 axis in intestinal cells, but not in hepatocytes. We conclude that targeting FGFR4 in the liver to activate the intestinal FXR-FGF15 axis may be a promising strategy for the treatment of NAFLD and metabolic dysfunction.

2023-01-11 | GSE222499 | GEO